Navigation Links
Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck
Date:12/21/2011

SAN FRANCISCO, Dec. 21, 2011 /PRNewswire/ -- Acumen Pharmaceuticals announces today the termination by Merck Sharp & Dohme Corp., (formerly Merck & Co., Inc.) of a 2003 agreement, amended in 2006, under which Acumen granted Merck exclusive worldwide rights to develop and commercialize anti-ADDL antibody therapeutics and diagnostics for Alzheimer's disease.

Merck's decision to discontinue this anti-ADDL Alzheimer's program and terminate the Merck-Acumen license agreement was based on internal strategic priorities. Under the termination provisions of the agreement, Acumen regains rights licensed to Merck, and also receives certain rights to patent applications and know how generated during the term of the Agreement. Anti-ADDL antibodies have high selectivity for soluble amyloid beta oligomers versus monomeric amyloid beta peptides or insoluble amyloid beta aggregates. Acumen believes this selectivity will favorably differentiate Acumen anti- ADDL immunotherapies compared to amyloid beta immunotherapies currently in late stage clinical testing.

"Acumen is very pleased to regain worldwide rights for the development and commercialization of anti-ADDL antibody therapeutics and diagnostics," stated Grant Krafft, Acumen's Chairman and Chief Science Adviser.

Acumen's Board of Directors also announces the appointment of Franz Hefti, Ph.D. as Acumen's President and CEO. Dr. Hefti has served as a Director of Acumen since 2008 and has a distinguished record in drug development and biotechnology ventures. Dr. Hefti served as Chief Science Officer for Avid Radiopharmaceuticals, which Eli Lilly & Co. acquired in 2010 for its Alzheimer's imaging product, Amyvid™. Prior to Avid, Dr. Hefti was Executive Vice President of Drug Development for Rinat Neuroscience Corporation where he led preclinical and clinical drug development efforts for three antibody drug candidates. The success of these programs led to Pfizer's 2006 acquisition of Rinat.
'/>"/>

SOURCE Acumen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
7. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
8. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
11. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Budding Biomedical Scientists , This ... participated in the Scientific Enrichment and Opportunity ... of Medicine . , The rigorous ... experience in the sciences and brings them in ... students for both academic and career mentoring. , ...
(Date:8/26/2014)... 2014  NeuroSigma, Inc., a Los Angeles ... technologies, today announced that it has filed a registration ... Exchange Commission relating to a proposed initial public offering ... be offered and the price range for the proposed ... LLC will act as the book-running manager for the ...
(Date:8/26/2014)... , Aug. 26, 2014 An analysis ... structures of all Mers CoV virus strains ... structures back to 2012.  This conservation and sharing of ... a Synthetic Mers CoV Blocker-Vaccine™ candidate, as it did for ... vaccine, both of which have been found to be ...
(Date:8/26/2014)... of engineers from Singapore has successfully piloted the ... satellite communications. , With the weight of payloads ... a lightweight, low power-consuming, wireless communication system to ... always been a challenge for system designers. , ... of Nanyang Technological University in Singapore launched VELOX-I, ...
Breaking Biology Technology:Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2ZigBee in the Sky 2
... move aside. Tiny gold stars, smaller than a billionth ... to medical diagnoses or testing for environmental contaminants. , While ... sciences, a new study by Duke University bioengineers indicates that ... above all the rest for certain applications. , The ...
... Stock Exchange Symbol: MS, EDMONTON, Nov. 6 ... developer in the treatment of multiple sclerosis (MS), ... quarter ended,September 30, 2008. BioMS Medical, in partnership ... (MBP8298), a drug for the,treatment of MS undergoing ...
... ... LymphoStat-B(R) Phase 3 trials; first Phase 3 ... in mid-2009 - ... Genome Sciences,Inc. (Nasdaq: HGSI ) today announced financial results and key developments,for the quarter ended September ...
Cached Biology Technology:Gold nanostar shape of the future 2Gold nanostar shape of the future 3BioMS Medical Announces Third Quarter 2008 Results 2BioMS Medical Announces Third Quarter 2008 Results 3BioMS Medical Announces Third Quarter 2008 Results 4BioMS Medical Announces Third Quarter 2008 Results 5Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 2Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 3Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 4Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 5Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 6Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 7Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 8Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 9Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 10
(Date:8/25/2014)... manipulating the behavior of ants emits a cocktail ... its natural target host, but not when infecting ... findings, which suggest that the fungus "knows" its ... mechanisms underlying this phenomenon, according to researchers., "Fungi ... chemicals that affect their environment," noted lead author ...
(Date:8/25/2014)... as a lightning strike on August 12, 2014. Currently ... There are close to 2,000 personnel working on ... fires and a number of large ones. Most of ... about 100 acres. An inversion layer settled over the ... 24, keeping fire activity moderate. As the inversion lifted in ...
(Date:8/25/2014)... 25, 2014  Scribe Labs unveiled its first ... and saw its campaign surpass the $50,000 funding ... kinematic metrics that help an athlete understand how ... their running mechanics. Built with an advanced 9-axis ... most advanced set of running metrics available outside ...
Breaking Biology News(10 mins):Zombie ant fungi 'know' brains of their hosts 2Zombie ant fungi 'know' brains of their hosts 3Happy Camper and July Fire Complexes in California 2runScribe Fitness Wearable Exceeds 200% of Kickstarter Goal in First Week 2
... by the University of Colorado at Boulder and the ... liquid crystals of ultrashort DNA molecules immersed in water, ... the emergence of life on Earth. CU-Boulder ... surprisingly short segments of DNA, lifes molecular carrier of ...
... quack-quack there. Farmers may find phytochemicals to be the ... in the bucket that cashes in on the tug-o-war ... the Texas Agricultural Experiment Station. Thats because applying ... increases disease-preventing phytochemicals, or nutrients, for which consumers may ...
... in remote parts of the UK, southern Scandinavia and ... dissolved organic matter. In this weeks Nature journal (22 ... (University College London) and the US Environmental Protection Agency ... a return to a more natural, pre-industrial state following ...
Cached Biology News:Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth 2Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth 3Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth 4Old McDonald had a phytochemical 2Old McDonald had a phytochemical 3Don't judge a brook by its color -- brown waters are more natural 2
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: